Your browser doesn't support javascript.
loading
A randomized control trial to test the effect of pegbovigrastim treatment at dry-off on plasma and milk oxylipid profiles during early mammary gland involution and the postparturient period.
Strickland, Jaimie M; Leite de Campos, Juliana; Gandy, Jeff; Mavangira, Vengai; Ruegg, Pamela L; Sordillo, Lorraine.
Afiliación
  • Strickland JM; College of Veterinary Medicine, Comparative Medicine and Integrative Biology, Michigan State University, East Lansing, MI 48824. Electronic address: strick51@msu.edu.
  • Leite de Campos J; College of Agriculture and Natural Resources, Animal Science, Michigan State University, East Lansing, MI 48824.
  • Gandy J; College of Veterinary Medicine, Comparative Medicine and Integrative Biology, Michigan State University, East Lansing, MI 48824.
  • Mavangira V; College of Veterinary Medicine, Iowa State University, Ames, IA 50011.
  • Ruegg PL; College of Veterinary Medicine, Comparative Medicine and Integrative Biology, Michigan State University, East Lansing, MI 48824.
  • Sordillo L; College of Veterinary Medicine, Comparative Medicine and Integrative Biology, Michigan State University, East Lansing, MI 48824.
J Dairy Sci ; 107(7): 5070-5089, 2024 Jul.
Article en En | MEDLINE | ID: mdl-38246537
ABSTRACT
The early period of mammary gland involution is a critical juncture in the lactation cycle that can have significant effects on milk production and mammary gland health. Pegbovigrastim (PEG) administered 1 wk prior and on the day of parturition can enhance immune function and reduce the incidence of mastitis in the early postpartum period. Oxylipids are potent metabolites of polyunsaturated fatty acids (PUFA) and are important mediators of inflammation. The objective of this study was to evaluate effects of PEG given 1 wk before and at the day of dry-off (D0) on concentrations of oxylipids in plasma and milk from 7 d before D0 to 14 d after, as well as the effects during the first 14 d of the subsequent lactation. We hypothesized that both pro- and anti-inflammatory oxylipids would vary based on initiation of mammary gland involution and that pegbovigrastim would affect oxylipid concentrations, particularly those related to leukocytes. A complete randomized blocked design was used to enroll cows into either a PEG treatment group (n = 10) or control group (n = 10; CON). Blood samples were collected -7, -2, -1, 0, 1, 2, 4, 7, and 14 d relative to dry-off and 5, 10, and 14 d postcalving. Samples were analyzed for PUFA and oxylipids in milk and plasma by ultra-performance mass spectrometry and liquid chromatography tandem quadrupole mass spectrometry, respectively. Overall, 30 lipid mediators were measured in both milk and plasma. Repeated measures analyses revealed a significant interaction of treatment by time for milk 8-iso-keto-15-prostaglandin E2, prostaglandin F2α, plasma 8,12-iso-prostaglandin Fα-VI, 11-hydroxyeicosatetraenoic acid, and 12-hydroxyheptadecatienoic acid. The majority of milk PUFA and oxylipids differed significantly during early mammary gland involution and into the early postpartum period. This study demonstrated changes in oxylipids in milk secretions and plasma during early involution, and further investigation may illuminate multiple complex processes and reveal targets for optimization of mammary gland involution.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Lactancia / Leche / Periodo Posparto / Oxilipinas / Glándulas Mamarias Animales Tipo de estudio: Clinical_trials Límite: Animals Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Lactancia / Leche / Periodo Posparto / Oxilipinas / Glándulas Mamarias Animales Tipo de estudio: Clinical_trials Límite: Animals Idioma: En Año: 2024 Tipo del documento: Article